We have observed
9 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after February 25, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTER OF VEGFA GENE AND THEIR USE AS PREDICTIVE MARKERS FOR ANTI-VEGF TREATMENTS
METHOD OF PRODUCTION OF SIALYLATED ANTIBODIES
COMPOSITION COMPRISING AFLIBERCEPT, FOLINIC ACID, 5-FLUOROURACIL (5-FU) AND IRINOCETAN (FOLFIRI)
COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME
ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT
ANTI-CEACAM5 ANTIBODIES AND USES THEREOF
METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER
STABLE LIQUID FORMULATION FOR MONOCLONAL ANTIBODIES